GMAB – Genmab A/S

Latest News & Stock Analysis

Genmab A/S, trading under the ticker GMAB, is a leading international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer and other serious diseases. Genmab’s innovative business model focuses on creating and developing fully human antibody products, often in collaboration with strategic partners, to drive future growth and deliver significant advances in patient care. Investors interested in biotechnology stocks will find that Genmab’s focus on novel antibody technologies offers unique investment opportunities. Stay updated with the latest news on GMAB, market trends, and in-depth stock analysis to make informed investment decisions.

Genmab Trade Illustrates Power of Cutting Losses
GMAB

Genmab Trade Illustrates Power of Cutting Losses

by | 12/04/2025 09:00 AM | GMAB

🔪 An investor case study showed selling Genmab after a 32% loss prevented a much larger 65% decline, highlighting the 'assassin' strategy.

⏱️ Setting predefined stop-loss levels, like 20-33%, can protect capital by forcing sales before drawdowns become unrecoverable.

📉 While cutting losses limits upside if a stock recovers, it crucially preserves capital for future, potentially better opportunities.

Read more!